Grapheton – Brain Machine Technology (BMI)
In addition to US Nuclear Corp’s (OTCQB: UCLE) strategic partnership and 40% stake in Grapheton, CEO Robert Goldstein has recently taken a seat on Grapheton’s board of directors and will now serve as Chief Strategy Officer.
Grapheton’s implantable bioelectronic sensors can be used to help treat millions of people worldwide suffering from mobility problems.
Neuroscientists stress there is a large unmet demand to develop implantable sensors and the artificial intelligence required to translate the brain signals into specific commands or actions to prosthetics.
Grapheton has already developed various types of implantable brain sensors, including ECoG (electrocorticography- monitoring the electrical activity of the brain), spinal stimulation probes, and brain chemical sensors, all of which are already in use at various research centers.
Unlike most other developers, Grapheton’s probes are biocompatible, thus avoiding inflammation. Grapheton already has several other patented advantages that solve some of the issues with the current technology.
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .